GlassScriptPhysician profile
Stephen Schreibman
NPI 1659480929
$933.20
in general payments reported to CMS, 2019-2025
12 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2022: $66.12 · 2023: $211 · 2024: $137 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $285.36 | 2023-2025 | Pemazyre, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $138.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.29 | 2024-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $123.68 | 2023-2025 | Keytruda |
| Daiichi Sankyo INC. | $62.71 | 2022-2023 | Injectafer |
| Aimmune Therapeutics, INC. | $44.52 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $29.91 | 2022 | |
| Servier Pharmaceuticals LLC | $29.61 | 2025 | |
| Amgen INC. | $23.96 | 2019 | |
| Vivus LLC | $22.68 | 2025 | Pancreaze |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schreibman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.